Dr. Roland Van Kimmenade and I discuss: Liberal Fluid Intake Versus Fluid Restriction In Chronic Heart Failure March 30, 2025 Disclosures: TBD
Dr. Sergio Raposeiras Roubin and I Discuss: Dapagliflozin In Patients Undergoing Transcatheter Aortic Valve Implantantion March 29, 2025 Disclosures: TBD Copyright NEJM
Dr. Antonius Buescher and I discuss: Development And External Validation Of A Deep Learning Electrocardiogram Model For Risk Stratification Of Coronary Revascularization Need In The Emergency Department March 29, 2025 Disclosures: TBD
Dr. Luke Laffin and I discuss: Efficacy Of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled Hypertension On A Standardized Antihypertensive Medication Regimen March 29, 2025 Disclosures: TBD
Dr. Hyo-Soo Kim and I discussed the HOST-BR trial on optimal DAPT duration and thrombosis-bleeding balance in ACS patients. 3-month DAPT reduced thrombosis vs. 1-month in high bleeding risk, and reduced bleeding vs. 12-month in low-risk patients March 29, 2025 Disclosures: TBD
Dr. Keyvan Karkouti and I discussed the FARES-II trial. PCC is superior to FP for hemostasis in managing excessive bleeding among cardiac surgery ptS with coagulopathy. March 29, 2025 Disclosures: TBD
Dr. Marc Bonaca and I discussed the STRIDE trial. Semaglutide improves functional outcomes in DM pts with symptomatic PAD, addressing a critical unmet need. March 29, 2025 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss new oral semaglutide and the SOUL trial which lowered death, MI and stroke rates by 14% in patients with diabetes. December 18, 2024 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff and Dr. C Michael Gibson discuss the SURMOUNT 1 Trial of Tirzepatide and how we may be able to diminish the progression from pre-diabetes to diabetes. December 9, 2024 Disclosures: TBD
Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN) November 18, 2024 Disclosures: TBD
